A5029008765- Pulmonary Hypertension Research and Treatments
- Cardiovascular Issues in Pregnancy
- Cardiovascular Function and Risk Factors
- Vascular Anomalies and Treatments
- Heart Failure Treatment and Management
- Cardiac Valve Diseases and Treatments
- Radiation Dose and Imaging
- Hemoglobinopathies and Related Disorders
- Cardiac Arrhythmias and Treatments
- Cardiac Imaging and Diagnostics
- Congenital Heart Disease Studies
- Antiplatelet Therapy and Cardiovascular Diseases
- Diabetes Treatment and Management
- Vascular Procedures and Complications
- Transplantation: Methods and Outcomes
- Atrial Fibrillation Management and Outcomes
- Effects of Radiation Exposure
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Liver Disease and Transplantation
- Aortic Disease and Treatment Approaches
- Peripheral Artery Disease Management
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Infective Endocarditis Diagnosis and Management
- Coronary Interventions and Diagnostics
- Advanced Radiotherapy Techniques
Onassis Cardiac Surgery Center
2014-2025
Pulmonary arterial hypertension (PAH) is a heterogenous clinical entity with poor prognosis, despite recent major pharmacological advances. To increase awareness about the pathophysiology, epidemiology, and management of disease, large national registries are required. The Hellenic pulmOnary hyPertension rEgistry (HOPE) was launched in early 2015 enrolls patients from all pulmonary subgroups Greece. Baseline epidemiologic, diagnostic, initial treatment data consecutive PAH presented this...
Balloon pulmonary angioplasty (BPA) is a novel and promising treatment option for patients with chronic thromboembolic hypertension (CTEPH) who are ineligible endarterectomy (PEA) those persistent or recurrent after PEA. We present the results of BPA procedures in CTEPH included Greek Pulmonary Hypertension Registry, evaluating real-life efficacy safety. analyzed data from 180 (2−17/patient, mean 8 ± 4/patient, 1248 dilated vessels, 0−18/session). Significant improvements were observed...
Whereas younger female patients were diagnosed with idiopathic pulmonary arterial hypertension (IPAH) in 1980s, it is now frequently encountered elderly cardiovascular comorbidities (CVCs) associated increased risk for left heart disease. We present data until November 2019 regarding specific features and clinical outcomes of IPAH population from the Hellenic Pulmonary Hypertension Registry (HOPE). Patients divided into two groups based on presence ≥ or <3 CVCs, hypertension, diabetes...
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a rare disease with poor prognosis if left untreated, characterized by pulmonary vascular bed obstruction due to unresolving thromboembolic material. The Hellenic hypertension registry (HOPE) was launched in Greece early 2015 and enrolls patients from all subgroups Greece. In total, 98 CTEPH were enrolled January until November 2019. Of these patients, 55.1% represented incident population, 50% classified the World Health Organization...
Background: transcatheter aortic valve implantation (TAVI) has emerged as an alternative to surgical replacement for patients with severe stenosis considered inoperable or at high operative risk, but the long-term outcome remains unknown. Hypothesis: we assessed 4-year clinical and echocardiographic outcomes of undergoing TAVI self-expanding Medtronic CoreValve prosthesis. Methods: sixty-three (mean age 80 ± 6 years) (AS) risk (Logistic EuroSCORE 28.8 10.9%) were included in this study....
Haemolytic anaemia represents a risk factor for the development of pulmonary hypertension (PH), currently classified as World Health Organization group 5 PH, and data regarding appropriate therapeutic strategy are limited. A total 28 patients, 85.7% with thalassaemia 14.3% sickle cell disease, diagnosis PH confirmed by right heart catheterization were included in study. The patients divided into three groups according to haemodynamic definition overall diagnostic approach: 42.9% had...
Haemolytic anaemia represents a risk factor for the development of pulmonary hypertension (PH), currently classified as World Health Organization group 5 PH and data regarding appropriate therapeutic strategy are limited. A total 28 patients, 85.7% with thalassemia 14,3% sickle cell disease, diagnosis confirmed by right heart catheterization, were included in study. The patients divided into three groups according to haemodynamics overall diagnostic approach: 42,9% had precapillary...
Pulmonary hypertension (PH) development remains a significant cardiovascular complication of haemoglobinopathies, severely affecting the morbidity and mortality such patients. According to 5th World Symposium on PH, PH related with chronic haemolytic anaemias is classified in group 5, mainly due multifactorial pathophysiology this patient population. There are no clear guidelines regarding management patients haemoglobinopathies; use specific pulmonary arterial (PAH) therapy β‐thalassaemia...
The effect of the reportedly low ionizing radiation doses, such as those very often delivered to patients in interventional cardiology, remains ambiguous. As cardiac procedures may have a significant impact on total collective effective dose, there are protection concerns for and physicians regarding potential late health effects. Given that doses (<100 mSv) expected be during these procedures, purpose this study was assess potency suitability current genotoxicity biomarkers detect...